Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of mRNA-1345 RSV vaccine in pregnant women and their infants
2023-505359-37-00Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing mRNA-1345 with Placebo (2 arms). Started Sep 2024; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2023-505359-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505359-37-00.